Abstract
Insulin resistance represents a fundamental metabolic anomaly that extends far beyond aberrant glucose homeostasis, acting as a primary driver in the pathogenesis of cardiovascular diseases. This condition paradoxically disrupts vascular endothelial function through pathway-specific signaling divergence. The impairment of the phosphatidylinositol-3-kinase (PI3K) dependent cascade severely diminishes nitric oxide bioavailability, while the compensatory hyperinsulinemia overstimulates the mitogen-activated protein kinase (MAPK) pathway, triggering robust vascular smooth muscle cell proliferation and excessive endothelin-1 secretion. The primary objective of this prospective clinical investigation was to quantify the longitudinal impact of systemic insulin resistance on early subclinical markers of atherosclerosis, specifically flow-mediated dilation and carotid intima-media thickness, within a cohort of 245 adult patients exhibiting diverse metabolic profiles. Utilizing high-resolution Doppler ultrasonography and biochemical assays over an 18-month follow-up period, the analytical framework revealed a highly significant inverse correlation between baseline Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) indices and endothelial reactivity. Patients in the highest HOMA-IR quartile demonstrated a severe absolute reduction in flow-mediated dilation (down to 4.1 ± 1.2%) compared to the lowest quartile (8.9 ± 1.5%), alongside an accelerated carotid intima-media thickness progression rate of 0.14 mm annually. Elevated systemic hyperinsulinemia independently predicted the deterioration of vascular compliance, irrespective of classical lipid profile abnormalities. Repositioning insulin resistance from a secondary metabolic bystander to a primary cardiovascular therapeutic target offers profound preventive implications. Aggressive early modulation of insulin sensitivity via pharmacological and lifestyle interventions holds the capacity to definitively halt the atherogenic cascade prior to the onset of irreversible structural vascular remodeling.
References
1. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595-1607.
2. DeFronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia. 2010;53(7):1270-1287.
3. Muniyappa R, Sowers JR. Role of insulin resistance in endothelial dysfunction. Rev Endocr Metab Disord. 2013;14(1):5-12.
4. Ormazabal V, Nair S, Elfeky O, Aguayo C, Salomon C, Zuñiga FA. Association between insulin resistance and the development of cardiovascular disease. Cardiovasc Diabetol. 2018;17(1):122.
5. Adeva-Andany MM, Martínez-Rodríguez J, González-Lucán M, Fernández-Fernández C, Castro-Quintela E. Insulin resistance is a cardiovascular risk factor in humans. Diabetes Metab Syndr. 2019;13(2):1449-1455.
6. Hill MA, Yang Y, Zhang L, Sun Z, Jia G, Parrish AR, et al. Insulin resistance, cardiovascular stiffening and cardiovascular disease. Metabolism. 2021; 119:154766.
7. Bornfeldt KE, Tabas I. Insulin resistance, hyperglycemia, and atherosclerosis. Cell Metab. 2011;14(5):575-585.
8. Laakso M, Kuusisto J. Insulin resistance and hyperglycaemia in cardiovascular disease development. Nat Rev Endocrinol. 2014;10(8):469-478.
9. Gastaldelli A, Gaggini M, DeFronzo RA. Role of solid organs in insulin resistance. Curr Opin Clin Nutr Metab Care. 2017;20(4):245-251.
10. Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017. Cardiovasc Diabetol. 2018;17(1):83.
11. Semenkovich CF. Insulin resistance and atherosclerosis. J Clin Invest. 2006;116(7):1813-1822.
12. Ginsberg HN, MacCallum PR. The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: Part I. Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus. J Clin Pharmacol. 2009;49(11):1364-1372.
13. Lee CH, Woo YC, Chow WS, Cheung CYY, Fong CHY, Yuen MMA, et al. Role of insulin resistance in endothelial dysfunction and subsequent cardiovascular events. Eur Heart J. 2020;41(40):3940-3948.
14. Varghese SP, Giallauria F, Vigorito C, et al. Endothelial dysfunction in insulin resistance: specific mechanisms and clinical implications. Int J Cardiol. 2022; 348:120-128.
15. Artunc F, Schleicher E, Weigert C, Baumann D. The impact of insulin resistance on the cardiovascular system and its implications for therapy. Rev Endocr Metab Disord. 2023;24(1):31-45.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.